The market access experts Dr. Stefan Walzer and Heather Wellam are discussing the market access process in Japan, one of the largest health care markets in the world!

In Japan not all products need to go through the full process, so an important question is, what the criteria are and what role does cost-effectiveness play in this market? What are the differences in the process between drugs and medical devices?

On top, the two experts are also discussing the opportunity to apply for price premiums in the reimbursement process. 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #drugs #medtech #japan

Since the original publication of this podcast, AI has received enormous public attention, and we have also seen an amazing increase in performance. This makes this discussion even more relevant - with this REPOST we want to give you the opportunity to hear it, in case you missed the first publication.

Dr. Stefan Walzer, market access expert, and his guest Dr. Andree Battes, expert in artificial intelligence (AI), are discussing the future of market access within the health care industry. How could AI support market access planning, submissions and negotiations, especially with the ever-increasing data? How could AI be beneficial in defining an optimal price anchor? And finally, would AI substitute the market access manager roles within the industry?

Further reading is available on "How to Embed AI into the Market Access Process“:  https://eularis.com/resources 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #ai #artificialintelligence

A strong evidence package is important as a solid base for health technology assessments and the following price negotiations with health care payers. It is widely agreed, that randomized controlled trials are the gold standard in HTA, but there are also strong advocates of real-world evidence as a complementary way to measure the effectiveness of treatments. 

One of these advocates is Dr. Karen Facey and so Dr. Stefan Walzer brought her on the podcast and asked all the tough questions about real world evidence and the reality with payers around the world. Are there opportunities in such RWE data or is that a dead-end? 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #hta #pharma #healthcare #realworldevidence #rwe